Upadacitinib

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA Giant Cell Arteritis and Takayasu Arteritis and Hidradenitis Suppurativa.

Type of Molecule

Small Molecule

Target

JAK1

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Ankylosing Spondylitis n/a
Atopic Dermatitis n/a
Axial SpA n/a
Phase 3
Crohn's Disease n/a
Phase 3
Giant Cell Arteritis n/a
Phase 3
Psoriatic Arthritis n/a
Rheumatoid Arthritis US - Approved, EU - Submitted
Approved
Takayasu Arteritis n/a
Phase 3
Ulcerative Colitis n/a
Phase 3
Hidradenitis Suppurativa n/a
Phase 2